Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 365

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 365
---
 (€ per share)                  ( 0.73)                                       ( 0.09)      ( 0.61)                  

21)Events after the reporting date

• On January 27, 2025, the Company announced the first patient was dosed in its Phase 1 study (NCT06781983), investigating the safety and tolerability of IPH4502, an innovative Antibody-Drug Conjugate (ADC), in patients with advanced solid tumors known to express Nectin-4. The Phase 1, open-label, multi-center study, includes a Part 1 Dose Escalation and a Part 2 Dose Optimization, and will assess the safety, tolerability, and preliminary efficacy of IPH4502 as a single agent in advanced solid tumors known to express Nectin-4, including but not limited to urothelial carcinoma, non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers. The study plans to enroll approximately 105

• On February 3, 2025, Mr. Arvind Sood resigned from his position as member of the Executive Board and left the Company February 27, 2025 and until that date he has remained EVP, President US Operations. The position of Vice President, President of U. S. Operations is not contemplated to be filled at this time.

• On February 17, 2025, the Company announced that the U. S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody, for the treatment of adult patients with relapsed or refractory (r/r) Sézary syndrome (SS) after at least 2 prior systemic therapies including mogamulizumab.

• On March 26, 2025, the Company announced that it plans to ask to the next General Meeting to be held on May 22, 2025 to transform into a société anonyme with a Board of Directors (" conseil d'administration"). This transformation is part of a strategic move to simplify and align Innate's corporate governance with international standards. If the General Meeting approves this change, it will be asked to appoint as members to the Board of Directors: Irina Staatz-Granzer, Pascale Boissel, Sally Bennett, Véronique Chabernaud, Bpifrance (represented by Olivier Martinez